SFTPD and idiopathic pulmonary fibrosis: These findings are consistent with a retrospective analysis of data from 56 patients with IPF, which showed that levels of SP-D and CA-125 significantly increased over 1 year in untreated subjects with IPF, but decreased in subjects treated with nintedanib [18].